



IPW

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Carl G. Hellerqvist et al.)
)
Serial No. **10/823,506**)
)
Filed: **April 12, 2004**)
)
For: **GBS Toxin Receptor**)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO-1449, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of each cited item is enclosed unless stated otherwise hereinbelow.

Pursuant to 37 C.F.R. §1.98(d), inasmuch as this application relies on prior application Serial No. 09/359,167 filed July 21, 1999, no copy of any patent, publication or other information previously cited by or submitted to the Office in such prior application is being provided herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 27, 2004.

Elena S. Polovnikova

Elena S. Polovnikova - Reg. No. 52,130

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Elena S. Polovnikova".

Elena S. Polovnikova, Ph.D.
Patent Agent
Reg. No. 52,130

KILPATRICK STOCKTON LLP
1100 Peachtree Street; Suite 2800
Atlanta, Georgia 22100-0202
Our Docket: 49530-299673 (22100-0202)

Under the Paperwork Reduction Act of 1996 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/823,506
Filing Date	April 12, 2004
First Named Inventor	Carl G. Hellerqvist
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	22100-0202 (49530-299673)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known		
		Application Number	10/823,506	
		Filing Date	April 12, 2004	
		First Named Inventor	Carl G. Hellerqvist	
		Group Art Unit	Not yet assigned	
		Examiner Name	Not yet assigned	
Sheet		of	Attorney Docket Number	22100-0202 (49530-299673)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	13	DEVORE <i>et al.</i> , "Phase I Study of the Antineovascularization Drug CM101," <i>Clinical Cancer Research</i> , Vol. 3, pp. 365-372 (1997)	
	14	FU, <i>et al.</i> , "Expressional Cloning of CM101 Receptor Gene from Mammalian Cells," <i>Proceedings of the American Association of Cancer Research</i> , Abstract No. 3677, Vol. 40, p. 557 (1999)	
	15	GEARING, <i>et al.</i> , "Expression Cloning of a Receptor for Human Granulocyte-Macrophage Colony-Stimulating Factor," <i>The EMBO Journal</i> , Vol. 8, No. 12, pp. 3667-3676 (1989)	
	16	HELLERQVIST <i>et al.</i> , "Anti-Tumor Effects of GBS Toxin are Caused by Induction of a Targeted Inflammatory Reaction," <i>Angiogenesis: Molecular Biology, Clinical Aspects</i> , Edited by Maragoudakis <i>et al.</i> , Plenum Press, New York, pp. 265-269 (1994)	
	17	HELLERQVIST <i>et al.</i> , "Antitumor Effects of GBS Toxin: A Polysaccharide Exotoxin From Group B β -Hemolytic Streptococcus," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 120, pp. 63-70 (1993)	
	18	HELLERQVIST <i>et al.</i> , "Molecular Basis for Group B β -Hemolytic Streptococcal Disease," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, pp.51-55 (1987)	
	19	HELLERQVIST <i>et al.</i> , "Preliminary Results of a Phase I Trial of CM101 in Cancer Patients," <i>J. Cellular Biochemistry</i> , Suppl. 19B, p. 26 (1995)	
	20	HELLERQVIST <i>et al.</i> , "Studies on Group B β -Hemolytic Streptococcus. I. Isolation and Partial Characterization of an Extracellular Toxin," <i>Pediatr. Res.</i> , Vol. 15, pp. 892-898 (1981)	
	21	HILLIER, <i>et al.</i> , "zr59d01.rl Soares NhHMPu S1 Homo sapiens cDNA clone 667681 5' Similar to Tr:G507415 G507415 Brain Specific Na ⁺ -Dependent Inorganic Phosphate Cotransporter," Database EMBL - EMBEST20 'Online!', Entry HS1173506, Acc. No. AA258513 (March 19, 1997)	
	22	KOVACS <i>et al.</i> , "Fibrogenic Cytokines and Connective Tissue Production," <i>The FASEB Journal</i> , Vol. 8, pp. 854-861 (1994)	
	23	NORRBY, "Angiogenesis: New Aspects Relating to Its Initiation and Control," <i>APMIS</i> , Vol. 105, pp. 417-437 (1997)	
	24	POLVERINI, "The Pathophysiology of Angiogenesis," <i>Crit. Rev. Oral. Biol. Med.</i> , Vol. 6, No. 3, pp.230-247 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known		
		Application Number	10/823,506	
		Filing Date	April 12, 2004	
		First Named Inventor	Carl G. Hellerqvist	
		Group Art Unit	Not yet assigned	
		Examiner Name	Not yet assigned	
Sheet		of	Attorney Docket Number	22100-0202 (49530-299673)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	25	QUINN, <i>et al.</i> , "CM101, A Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing in Murine Models," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 121, pp.253-256 (1995)	
	26	THURMAN, <i>et al.</i> , "Actue Inflammatory Changes in Subcutaneous Microtumors in the Ears of Mice Induced by Intravenous CM101 (GBS Toxin)," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 122, pp. 549-553 (1996)	
	27	WAMIL, <i>et al.</i> , "Soluble E-Selectin in Cancer Patients as a Maker of the Therapeutic Efficacy of CM101, a Tumor-Inhibiting Anti-Neovascularization Agent, Elevated in Phase I Clinical Trail," <i>J. Cancer Res. Clin. Oncol.</i> , Vol. 123, pp. 173-179 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.